A new diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer.
Current tests such as the prostate specific antigen (PSA) and digital rectal exam (DRE) often lead to unneeded biopsies and more than 50% of men who undergo biopsy do not have prostate cancer, yet suffer the pain and side effects of the procedure such as infection or sepsis.
Less than 20% of men who receive a prostate biopsy are diagnosed with the aggressive form of prostate cancer that could most benefit from treatment. A newly developed diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer. The test incorporates a unique nanotechnology platform to make the diagnostic using only a single drop of blood, and is significantly more accurate than current screening methods.
No comments:
Post a Comment